Prognostic significance of pretransplant (18)F-FDG PET/CT metrics in relapsed/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation

自体干细胞移植前,对挽救性化疗有部分反应的复发/难治性弥漫性大B细胞淋巴瘤患者进行移植前(18)F-FDG PET/CT指标的预后意义

阅读:5

Abstract

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients with partial response (PR) to salvage chemotherapy show heterogeneous outcomes after autologous stem cell transplantation (ASCT). Current visual positron emission tomography (PET) assessment inadequately identifies patients likely to benefit from transplantation. We retrospectively evaluated the prognostic value of semiquantitative metrics from interim (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in 50 R/R DLBCL patients with PR to salvage chemotherapy who underwent ASCT. PET/CT scans were analysed visually using the Deauville 5-point scale and semiquantitatively using relative metrics measuring percentage maximum standardized uptake value (SUVmax) changes between baseline and interim scans (%ΔSUVmax-variants) and absolute metrics including tumour-to-liver SUV ratios (SUVTLR). Cut-off values were determined using quartile-based analysis. With a median follow-up of 107 months (range, 1.2-191.3), the median event-free survival (EFS) was 9.87 months. Interim SUVTLR ≥4.2 was the predictor of inferior EFS (hazard ratio [HR] 1.25, p = 0.002), while the percentage change in the hottest lesion's SUVmax (%ΔSUVmax-index) also showed prognostic significance (HR 0.91, p = 0.043). In contrast, visual Deauville scores at interim PET showed no prognostic difference between scores 4 and 5 (p = 0.094 for EFS). Therefore, semiquantitative PET metrics, particularly interim SUVTLR of 4.2, can provide prognostic information beyond visual assessment in PR patients prior to ASCT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。